Migraine meds put to the test in Real-World study

NCT ID NCT05827887

Completed Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 226 adults in Israel who were prescribed ubrogepant or atogepant for their migraines. Researchers wanted to see how satisfied people were with these drugs in real-world settings, not just in a lab. Participants used an app to track their experience over 90 days, and the main goal was to measure treatment satisfaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Locations

Assuta Ashdod Medical Center /ID# 260020

Ashdod, Southern District, 7747600, Israel
Clalit HMO /ID# 257364

Gani Tikva, 5591236, Israel
Edith Wolfson Medical Center /ID# 269740

Holon, Central District, 5822012, Israel
Hadassah Medical Center-Hebrew University /ID# 257352

Jerusalem, 91120, Israel
Maccabi Healthcare Services /ID# 254171

Kfar Saba, Central District, 4420123, Israel
Meir Medical Center /ID# 254170

Kfar Saba, Central District, 4428164, Israel
Shaare Zedek Medical Center /ID# 254169

Jerusalem, Jerusalem, 91031, Israel
Soroka University Medical Center /ID# 254551

Beersheba, Southern District, 8410101, Israel
Tel Aviv Sourasky Medical Center /ID# 263089

Tel Aviv, Tel Aviv, 6423906, Israel
The Chaim Sheba Medical Center /ID# 254550

Ramat Gan, Tel Aviv, 5265601, Israel
ZIV Medical Center /ID# 257360

Safed, Northern District, 13100, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.